In this episode of Curing with Sound, Zhen Xu, PhD, the Li Ka Shing Endowed Professor of Biomedical Engineering at the University of Michigan, discusses histotripsy. Dr. Xu and her colleagues developed histotripsy, the first noninvasive, nonthermal ultrasound ablation technique that received FDA approval for liver tumor treatment in 2023. Her work has led to multiple clinical trials on histotripsy treatment for malignant and benign tumors.
Dr. Xu shares the 20-year journey from initial discovery to clinical application and highlights histotripsy's remarkable ability to mechanically break down targeted tissue without incisions or radiation. She also recounts inspiring patient stories from clinical trials, including patients who experienced no pain and returned to normal activities immediately after treatment.
Histotripsy Lab: histotripsy.umich.edu
Connect on Linked In: Dr. Zhen Xu
EPISODE TRANSCRIPT
----------------------------
QUESTIONS?
Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.
Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.
FUSF SOCIAL MEDIA
FUSF WEBSITE
https://www.fusfoundation.org
SIGN UP FOR OUR FREE NEWSLETTER
https://www.fusfoundation.org/newsletter-signup/
READ THE LATEST NEWSLETTER
https://www.fusfoundation.org/the-foundation/news-media/newsletter/
DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK)
https://www.fusfoundation.org/read-the-tumor-by-john-grisham/